← All trials
NCT04821648
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2021
- Primary completion
- Dec 1, 2021
- Completion date
- Dec 31, 2021
- First posted
- Mar 29, 2021
- Last posted
- Aug 23, 2021
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rejuven Dermaceutical Co., Ltd.Lead sponsor
- Rejuven Dermaceutical Co., Ltd.Reponsible party - principal investigator
- Arizona Research AssociatesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.